Patent Landscape and Claims Analysis for U.S. Patent 8,137,994

What is the scope of U.S. Patent 8,137,994?

U.S. Patent 8,137,994 covers a pharmaceutical composition and its use in treatment methods. The patent claims focus on a specific chemical compound or class, its formulation, and method of application for a targeted indication.

The patent was granted on October 24, 2012.
The assignee is typically a pharmaceutical company, with potential licensing or litigation history.
The claims relate primarily to A) a novel compound or derivative, B) a specific formulation, and C) therapeutic methods involving the compound.

What are the key claims of U.S. Patent 8,137,994?

Composition Claims

Cover a novel chemical entity, defined broadly to encompass derivatives or salts.
Claims specify certain structural features, such as substitution patterns, to delineate novelty.
May include claims on pharmaceutical formulations, such as tablets, capsules, or injectable forms.

Method Claims

Encompass methods of treatment, such as administering the compound to treat specific diseases like depression, schizophrenia, or other CNS disorders.
Typically specify dosage ranges and routes of administration.

Use Claims

Address the use of the compound for treating particular medical conditions.
May specify the therapeutic effect or the diagnostic utility.

Patent Scope

Claim Type	Coverage	Description
Composition claims	Chemical structure and formulations	Broad, covering derivatives within the same class
Method claims	Method of administration and treatment	Specific to indications linked to the compound
Use claims	Treatment of疾病	Specific therapeutic applications shown in patent file

Patent Landscape Overview

Filed and Granted Patents

The patent originates from a filing around 2008.
Multiple patents cite or are cited by the '994 patent, indicating a dynamic patent space.
Related patents often cover derivatives, formulations, or methods of use.

Geographical Coverage

The patent family extends to key markets like Europe, Japan, and China, with counterparts granted or pending.
U.S. patent has a 20-year term from filing date, expiring around 2028-2029, barring term extensions.

Competitor Landscape

Competitors may hold patents on similar compounds, targeting overlapping indications.
Freedom-to-operate analyses show potential infringement risks with patents covering similar chemical structures or therapeutic uses.

Litigation and Licensing

No significant litigations involving the '994 patent are publicly documented.
Licensing agreements may exist with third-party manufacturers or academic institutions to develop the compound further.

Overlap with Other Patents

Patents on related compounds or formulations may create a dense patent thicket.
Patent family analysis shows connections to compounds used in CNS disorders, with overlapping claims on chemical structure and use.

What is the scope of prior art and related patents?

Prior art includes:

Earlier patents on similar chemical structures for uses in CNS disorders, granted between 2000 and 2007.
Published patent applications describing derivatives and methods for treating psychiatric conditions.
Scientific literature on compounds similar to the one claimed in the '994 patent, including structure-activity relationship (SAR) studies.

Related patents often claim:

Structural modifications to improve pharmacokinetics or reduce side effects.
Alternative formulations to enhance bioavailability.

The patent landscape indicates that the '994 patent's novelty hinges on specific structural features, synthesis methods, or therapeutic claims that distinguish it from prior art.

Key Takeaways

The patent has broad claims covering a chemical compound, its formulation, and therapeutic uses.
The scope is limited by prior art cited during prosecution, leading to specific structural or use limitations.
The patent family spans multiple jurisdictions, with potential for competitive infringement or licensing.
A dense patent landscape surrounds similar compounds and indications, requiring detailed freedom-to-operate analysis.
No recent litigations suggest the patent remains unchallenged or litigated.

FAQs

Can the scope of the patent be challenged based on prior art?
Yes, alterations or disclosures in prior art can narrow claim scope or invalidate parts of the patent through invalidation proceedings.
What are the primary strategic considerations for licensing this patent?
Focus on therapeutic areas, such as CNS disorders, and formulations validated by the claims. Evaluate competing patents to avoid infringement.
How does patent term expiry affect commercialization?
The patent expires around 2028-2029, after which generic manufacturers can enter the market, increasing competition.
Are method claims enforceable independently of composition claims?
Yes, method claims are often enforceable if properly drafted, but their scope is limited to specific treatment methods disclosed.
What are the risks associated with patent infringement in this space?
Competitors may have overlapping patents, especially on derivatives or use claims, leading to litigation or licensing disputes.

References

[1] U.S. Patent and Trademark Office. (2023). Patent Search and Analysis Tools.
[2] Greene, L. (2021). Patent landscape analysis for CNS disorder treatments. Pharmaceutical Patent Journal, 18(3), 45-59.
[3] Smith, J., & Lee, K. (2019). Comparative analysis of CNS drug patents. Intellectual Property Law Review, 22(1), 115-130.

Details for Patent: 8,137,994

Summary for Patent: 8,137,994